| Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD PK Luukkonen, Y Zhou, PAN Haridas, OP Dwivedi, T Hyötyläinen, A Ali, ... Journal of hepatology 67 (1), 128-136, 2017 | 128 | 2017 |
| ST6GAL1: A key player in cancer R Garnham, E Scott, KE Livermore, J Munkley Oncology letters 18 (2), 983-989, 2019 | 127 | 2019 |
| Glycans as biomarkers in prostate cancer E Scott, J Munkley International journal of molecular sciences 20 (6), 1389, 2019 | 106 | 2019 |
| Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma Z Hall, D Chiarugi, E Charidemou, J Leslie, E Scott, L Pellegrinet, ... Hepatology 73 (3), 1028-1044, 2021 | 92 | 2021 |
| FUT8 alpha-(1, 6)-fucosyltransferase in cancer K Bastian, E Scott, DJ Elliott, J Munkley International Journal of Molecular Sciences 22 (1), 455, 2021 | 91 | 2021 |
| Targeting aberrant sialylation to treat cancer J Munkley, E Scott Medicines 6 (4), 102, 2019 | 77 | 2019 |
| The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma O Govaere, M Petz, J Wouters, YP Vandewynckel, EJ Scott, B Topal, ... Oncogene 36 (47), 6605-6616, 2017 | 69 | 2017 |
| Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer J Munkley, L Li, SRG Krishnan, G Hysenaj, E Scott, C Dalgliesh, HZ Oo, ... Elife 8, e47678, 2019 | 51 | 2019 |
| Genetics of alcoholic liver disease and non-alcoholic steatohepatitis E Scott, QM Anstee Clinical Medicine 18 (Suppl 2), s54, 2018 | 29 | 2018 |
| Tumour associated glycans: A route to boost immunotherapy? E Scott, DJ Elliott, J Munkley Clinica Chimica Acta 502, 167-173, 2020 | 26 | 2020 |
| Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth E Scott, K Hodgson, B Calle, H Turner, K Cheung, A Bermudez, ... Oncogene 42 (12), 926-937, 2023 | 18 | 2023 |
| Increased adipose tissue indices of androgen catabolism and aromatization in women with metabolic dysfunction G Ostinelli, S Laforest, SG Denham, MF Gauthier, V Drolet-Labelle, ... The Journal of Clinical Endocrinology & Metabolism 107 (8), e3330-e3342, 2022 | 10 | 2022 |
| Pro-survival factor edem3 confers therapy resistance in prostate cancer E Scott, R Garnham, K Cheung, A Duxfield, DJ Elliott, J Munkley International Journal of Molecular Sciences 23 (15), 8184, 2022 | 6 | 2022 |
| ST6GAL1‐mediated aberrant sialylation promotes prostate cancer progression E Scott, E Archer Goode, R Garnham, K Hodgson, M Orozco‐Moreno, ... The Journal of pathology 261 (1), 71-84, 2023 | 5 | 2023 |
| Engineering prostate cancer in vitro: what does it take? A Buskin, E Scott, R Nelson, L Gaughan, CN Robson, R Heer, ... Oncogene 42 (32), 2417-2427, 2023 | 4 | 2023 |
| The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer K Hodgson, M Orozco-Moreno, E Scott, R Garnham, K Livermore, ... Scientific Reports 13 (1), 17031, 2023 | 2 | 2023 |
| ST3 beta-galactoside alpha-2, 3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer R Garnham, D Geh, R Nelson, E Ramon-Gil, L Wilson, EN Schmidt, ... Communications Biology 7 (1), 276, 2024 | 1 | 2024 |
| Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer R Advani, S Luzzi, E Scott, C Dalgliesh, J Weischenfeldt, J Munkley, ... Oncogene 42 (43), 3161-3168, 2023 | 1 | 2023 |
| The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease O Govaere, J Palmer, M Zhuang, MYW Zaki, E Scott, S Cockell, AK Daly, ... Journal of Hepatology 68, S339-S339, 2018 | 1 | 2018 |
| A systematic review reveals conflicting evidence for the prevalence of antibodies against the sialic acid ‘xenoautoantigen’Neu5Gc in humans and the need for a standardised … E Hutton, E Scott, CN Robson, N Signoret, MA Fascione Frontiers in Molecular Biosciences 11, 1390711, 2024 | | 2024 |
